DK175207B1 - Sårbehandlingsmidler indeholdende thromboxan A2-receptor-antagonister - Google Patents
Sårbehandlingsmidler indeholdende thromboxan A2-receptor-antagonister Download PDFInfo
- Publication number
- DK175207B1 DK175207B1 DK198904315A DK431589A DK175207B1 DK 175207 B1 DK175207 B1 DK 175207B1 DK 198904315 A DK198904315 A DK 198904315A DK 431589 A DK431589 A DK 431589A DK 175207 B1 DK175207 B1 DK 175207B1
- Authority
- DK
- Denmark
- Prior art keywords
- thromboxane
- acid
- antagonist
- use according
- amino
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 7
- 208000027418 Wounds and injury Diseases 0.000 title description 5
- 239000003795 chemical substances by application Substances 0.000 title description 4
- 239000002464 receptor antagonist Substances 0.000 title description 3
- 229940044551 receptor antagonist Drugs 0.000 title description 3
- 102000003938 Thromboxane Receptors Human genes 0.000 title 1
- 108090000300 Thromboxane Receptors Proteins 0.000 title 1
- 206010052428 Wound Diseases 0.000 title 1
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 claims abstract description 18
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 claims description 15
- -1 4-cyclohexyl Chemical group 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 11
- 230000037380 skin damage Effects 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 claims description 6
- 239000005557 antagonist Substances 0.000 claims description 5
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 4
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 3
- VLMZAUCKMYJSGM-UHFFFAOYSA-N 2-[4-[3-(4-chlorophenyl)sulfonylpropyl]phenyl]acetic acid Chemical group C1=CC(CC(=O)O)=CC=C1CCCS(=O)(=O)C1=CC=C(Cl)C=C1 VLMZAUCKMYJSGM-UHFFFAOYSA-N 0.000 claims description 2
- DYWAPFDKPAHSED-UHFFFAOYSA-N 2-cycloheptyloxepane Chemical group C1CCCCCC1C1OCCCCC1 DYWAPFDKPAHSED-UHFFFAOYSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 150000003536 tetrazoles Chemical class 0.000 claims description 2
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 229960003424 phenylacetic acid Drugs 0.000 claims 1
- 239000003279 phenylacetic acid Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 27
- 229940123987 Thromboxane A2 receptor antagonist Drugs 0.000 abstract description 6
- 208000028990 Skin injury Diseases 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 238000003756 stirring Methods 0.000 description 12
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 230000000699 topical effect Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 8
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 8
- 239000012071 phase Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 229940099259 vaseline Drugs 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 229940031954 dibutyl sebacate Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 6
- 229920001214 Polysorbate 60 Polymers 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 4
- 229960002216 methylparaben Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 4
- 229960003415 propylparaben Drugs 0.000 description 4
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 4
- 239000004408 titanium dioxide Substances 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 238000002316 cosmetic surgery Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 235000011078 sorbitan tristearate Nutrition 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IULOBWFWYDMECP-UHFFFAOYSA-N 2-[4-[2-[(4-chlorophenyl)sulfonylamino]ethyl]phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1CCNS(=O)(=O)C1=CC=C(Cl)C=C1 IULOBWFWYDMECP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229940073669 ceteareth 20 Drugs 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000002278 reconstructive surgery Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 229940045860 white wax Drugs 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YURNCBVQZBJDAJ-UHFFFAOYSA-N 2-heptenoic acid Chemical compound CCCCC=CC(O)=O YURNCBVQZBJDAJ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UHZXPFSCJFEFPS-UHFFFAOYSA-N 7-(cyclohepten-1-yl)-2,3,4,5-tetrahydrooxepine Chemical class C1CCCCC=C1C1=CCCCCO1 UHZXPFSCJFEFPS-UHFFFAOYSA-N 0.000 description 1
- ZWAVGFSZMACJHA-PMNBYGLBSA-N 7-[2-Trifluoromethyl-4-(2-hydroxyphenyl)-1,3-dioxan-cis-5-yl]-hept-5z-enoic acid Chemical compound OC(=O)CCC\C=C/C[C@@H]1CO[C@H](C(F)(F)F)O[C@@H]1C1=CC=CC=C1O ZWAVGFSZMACJHA-PMNBYGLBSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000001154 Dermoid Cyst Diseases 0.000 description 1
- 206010069808 Electrical burn Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 108010069102 Thromboxane-A synthase Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 229940023184 after bite Drugs 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- KPSZWAJWFMFMFF-UHFFFAOYSA-N delta-Hexylen-alpha-carbonsaeure Natural products CC=CCCCC(O)=O KPSZWAJWFMFMFF-UHFFFAOYSA-N 0.000 description 1
- KPSZWAJWFMFMFF-NSCUHMNNSA-N delta-heptenoic acid Chemical compound C\C=C\CCCC(O)=O KPSZWAJWFMFMFF-NSCUHMNNSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 108010088012 loxosceles venom Proteins 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 239000002396 thromboxane receptor blocking agent Substances 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 229940100613 topical solution Drugs 0.000 description 1
- 229940061102 topical suspension Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Description
DK 175207 B1 i
Den foreliggende opfindelse angår midler til behandling af hudlæsioner hos pattedyrarter, hvilke midler indeholder en thromboxan-A2-receptorantagonist for at lette heling og/eller begrænse omfanget af sådanne hudlæsioner.
5 Det er kendt, at thromboxan-A2 spiller en rolle ved ischæmisk vævsbeskadigelse. En række undersøgelser af mennesker har vist, at aspirin, der er inhibitor af thromboxan-produktion, nedsætter forekomsten af hjerneblødning (cerebral ischæmi) og myocardieinfarkt (myocardieischæmi) hos visse 10 patientgrupper. Thromboxans rolle ved hudlæsion er mindre klar. Imidlertid tyder materiale fra dyreundersøgelser på, at thromboxan-A2 spiller en vigtig rolle ved hudbeskadigelse.
Thromboxan-A2 forekommer i brændt hud [J.P. Heggers, G.L. Loy, M.C. Robson og E.J. Del Beccaro, Histological 15 Demonstration of Prostaglandins and Thromboxanes in Burned Tissue, Journal of Surgical Research 28(2), 110-117 (1980)], og systemisk indgivet imidazol-methyl-prednisolon og topisk Dermoid Aloe, der er uspecifikke inhibitorer af thromboxan-produktion, formindsker skader efter elektriske forbrændinger 20 [M.C. Robson, R.C. Murphy og J.P. Heggers, A New Explanation for the Progressive Tissue Loss in Electrical Injuries, Plastic and Reconstructive Surgery 73(3), 431-437 (1984); og J.P. Heggers, M.C. Robson og L.S. Zachary, Thromboxane Inhibitors for the Prevention of Progressive Dermal Ischemia 25 Due to the Thermal Injury, Burn Care 6(6), 466-468 (1985)]. Adrenale steroider, indomethacin, aspirin og methimazol (alle uspecifikke inhibitorer af thromboxan-A2-syntese) bevarer hudens blodstrøm og forbedrer heling efter skoldningsforbrændinger [M.C. Robson, E.J. Del Beccaro og J.P.
ί 30 Heggers, The Effect of Prostaglandins on the Dermal Micro-circulation After Burning, and the Inhibition of the Effect by Specific Pharmacological Agents, Plastic and Reconstructive Surgery 63(6), 781-787 (1979); og E.J. Del Beccaro, M.C. Robson, J.P. Heggers og R. Swaminathan, The Use of Specific 35 Thromboxane Inhibitors to Preserve the Dermal Microcirculation After Burning, Surgery 87(2), 137-141 (1980)). Desuden
I DK 175207 B1 I
i 2 I
I forbedrer topisk indgift af imidazol eller UK 38485 eller U I
I 63557A (uspecifikke inhibitorer af thromboxan-A2-syntese) I
I heling af skoldningsforbrændinger [J.P. Heggers m.fl., Burn I
I Care 6(6), 466-468 (1985)]. Ved en model af traumatisk hud- I
I I
I 5 beskadigelse forøger UK 38485 vævsoverlevelse [L.S. Zachary, I
I J.P. Heggers, M.C. Robson og R.C. Murphy, Combined Prosta- I
I cyclin and Thromboxane Synthetase Inhibitor UK 38485 in I
I Flap Survival, Annals of Plastic Surgery 17(2), 112-115 I
I (1986)]. I
I 10 Desuden tyder resultaterne af in vitro-undersøgelser I
I på, at blodpladefrigørelsesreaktionen (en thromboxan-A2- I
I betinget proces) spiller en rolle ved den blodpladebeskadi- I
I gelse, der er forbundet med dermonecrose efter bid af den I
I giftige brune edderkop [R. Rees, J. Hawiger, R.M. Des Prez I
I 15 og L.E. King, Mechanism of Platelet Injury Associated with I
I Dermonecrosis Resulting from Brown Recluse Spider Venom, I
I Clinical Research 30, 265A (1982)]. I
I Indtil nu er der ved undersøgelser af thromboxan- I
I A2's rolle ved hudbeskadigelse blevet anvendt inhibitorer, I
I 20 der er uspecifikke, idet de ændrer produktionen af flere I
I stoffer ud over thromboxan-A2^ I
I Ifølge den foreliggende opfindelse er der nu til- I
I vejebragt et middel til behandling af hudbeskadigelser for- I
I årsaget af traumer eller varmeforbrændinger, hvor en throm- I
I 25 boxan-A2-receptorantagonist indgives systemtisk eller topisk I
I under og efter hudens eksposition for traumer eller var- I
I meforbrændinger for at lette heling og/eller begrænse omfan- I
I get af sådanne beskadigelser. I
I Desuden tilvejebringes der ved den foreliggende op- I
I 30 findelse et middel til forbyggelse og behandling af hudtryk- I
I skader, f.eks. liggesår, indeholdende en thromboxan-A2-re- I
I ceptorantagonist, og som indgives systemisk eller topisk på I
I huden før, under eller efter hudens eksposition for trykbe- I
I skadigelse. I
I 35 Thromboxan-A2-antagonister, som kan anvendes her, er I
I specifikke inhibitorer af thromboxan-A2's virkninger og I
DK 175207 B1 3 frembringer derfor den ønskede virkning med hensyn til throm-boxan-A2~inhibering uden at fremkalde andre uspecifikke virkninger, der kan være uønskede. Eksempler på sådanne thromboxan-A2-antagonister, der er egnet til brug i forbin-5 delse med den foreliggende opfindelse, omfatter, men er ikke begrænset til, de 7-oxabicycloheptan- og 7-oxabicyclo-heptenforbindelser, der er genstand for USA patentskrift nr. 4.537.981, især (lS-[la,2/3(5Z) ,3/3(lE,3R,4S) ,4a] ]-7-[3-(3-hydroxy-4-phenyl-l-pentenyl)-7-oxabicyclo[2,2,l]hept-2-10 yl]-5-heptensyre; de 7-oxabicycloheptan-substituerede amino-prostaglandin-analoge, der er genstand for USA patentskrift nr. 4.416.896, især [lS-[la,2/3(5Z),30,4a]]-7-[3-[[2-(phenyl-amino)carbonyl]hydrazino]methyl]-7-oxabicyclo[2,2,l]hept-2-yl]-5-heptensyre; de 7-oxabicycloheptan-substituerede diamid-15 prostaglandin-analoge, der er genstand for USA patentskrift nr. 4.663.336, især [IS-[ 1/3,2α (5Z) , 3a,4/3] ]-7-[3-[ [ [ [ (1-oxo-hepty 1) amino]acetyl]amino]methyl]-7-oxabicyclo[2,2,1]hept-2-yl]-5-heptensyre (SQ 30.471), som foretrækkes, og den tilsvarende tetrazol, samt [lS-[la, 2/3 (Z) , 3/?,4a] ]-7-(3-[( [[ (4-2 0 cyclohexy1-1-oxobutyl) amino]acetyl]amino]methyl]-7-oxabicy-clo[2,2,l]hept-2-y 1]-5-heptensyre; phenoxyalkylcarboxylsyrerne , der er omhandlet i USA patentskrift nr. 4.258.058, især 4 - [2-(benzensulfamido)ethyl]phenoxyeddikesyre (BM 13.177
Boehringer Mannheim), sulfonamidophenylcarboxylsyrerne om-25 handlet i USA patentskrift nr. 4.443.477, især 4-[2-(4-chlor-benzensulfonamido)ethylJphenyleddikesyre (BM 13.505, Boehringer Mannheim), arylthioalkylphenylcarboxylsyrerne anført i USA patentskrift nr. 4.752.676, især 4-(3-( (4-chlorphenyl)-v sulfonyl)propyl)benzeneddikesyre.
30 Andre eksempler på thromboxan-A2~inhibitorer, der er egnede til den foreliggende anvendelse, men ikke begrænset hertil, er (E)-5-[[[(pyridinyl)(3-(trifluormethyl)phenyl]me-thylen]amino]oxy]pentansyre, også omtalt som R68.070 - Janssen Research Laboratories, 3-[l-(4-chlorphenylmethyl)-5-35 fluor-3-methylindol-2-yl]-2,2-dimethylpropansyre [(L-655240 Merck-Frosst) Eur. J. Pharmacol. 135(2), 193 (17. marts
I DK 175207 B1 I
I 4 I
I 1987)], 5(Z)-7-([2,4,5-cis]-4-(2-hydroxyphenyl)-2-trifluor- I
I methyl-l,3-dioxan-5-yl)heptensyre (ICI 185282, Brit. J. I
I Pharmacol 90 (Proc. Suppl.), 228 P-Abs., marts 1987), 5(Z)- I
I 7-[2,2-dimethyl-4-phenyl-l, 3-dioxan-cis-5-yl]-heptensyre I
H
I 5 (ICI 159995, Brit. J. Pharmacol. 86 (Proc. Suppl.), 808 P- I
I Abs., december 1985), N,N'-bis[7-(3-chlorbenzenaminosul- I
I fonyl]-l,2,3,4-tetrahydro-isoquinolyl]disulfonylimid (SKF I
I 88046, Pharmacologist 25(3), 116 Abs, 117 Abs, august 1983), I
[lo (Z)-2β, 5α]-(+)—7 — [5—[[(1,l'-biphenyl)-4-yl]-methoxy)-2- I
I 10 (4-morpholinyl)-3-oxocyclopentyl]-4-heptensyre (AH 23848- I
I Glaxo, Circulation 72(6), 1208, december 1985, levallor- . I
I phanallylbromid (CM 32.191, Sanofi, Life Sci. 31 (20-21), I
I 2261, 15. november 1982), (Z,2-endo-3-oxo)-7-(3-acetyl-2- I
I bicyclo{2,2,l]-5-hepta-3Z-ensyre, 4-phenylthiosemicarbazon I
I 15 (EP092 - Univ. Edinburgh, Brit. J. Pharmacol. 84(3), 595, I
I marts 1985). I
I Midlet ifølge den foreliggende opfindelse med indhold I
I af thromboxan-A2~receptorantagonist indgives til pattedyr- I
I arter, såsom aber, hunde, katte, rotter og mennesker. I
I 20 Selv om thromboxan-A2_receptorantagonisten kan ind- I
I gives systemisk, såsom oralt eller parenteralt, fortrækkes I
I det, at thromboxan-A2-receptorantagonisten indgives lokalt, I
I så at den kan[absorberes i det beskadigede hudområde. Når I
I trykbeskadigelse, såsom liggesår, frembyder et problem, kan I
I 25 thromboxan-A2-receptorantagonisten ligeledes anvendes pro- I
fylaktisk. I
I De topiske midler, som kan anvendes, vil omfatte et I
I topisk bærestof, som kan foreligge i form af en cream, lo- I
I tion, salve, gel, lipofil stift, væske, pulver, aerosol el. I
I 30 lign. Eksempler på sådanne topiske bærestoffer er omhandlet * I
I i USA patentskrifterne nr. 3.892.856, 3,892.857, 4.082.881 I
I og 4.233.295. I
I Med hensyn til dosering af thromboxan-A2-receptor- I
I antagonist, vil den topiske tilberedning, når præparatet I
I 35 indgives topisk, indeholde fra ca. 0,01 til 5 vægt% throm- I
boxan-A2-receptorantagonist. Antallet af påføringer vil I
DK 175207 B1 5 afhænge af hudbeskadigelsens omfang. I reglen vil 1-5 behandlinger pr. dag i 5 dage være nødvendige. Hvis den topiske tilberedning derimod anvendes profylaktisk, kan den påføres, så længe risikoen for hudbeskadigelsen fortsætter.
5 Thromboxan-A2-antagonisten kan også inkorporeres i en gængs doseringsform, såsom en tablet, kapsel, eliksir eller injektion. De ovennævnte doseringsformer omfatter ligeledes det nødvendige bæremateriale, ekscipient, smøremiddel, puffer, antibakterielt middel, fyldstof (såsom man-10 nitol), antioxidanter (ascorbinsyre eller natriumbisulfit) el. lign. Orale doseringsformer foretrækkes, selv om paren-terale former også er helt tilfredsstillende.
Med hensyn til sådanne systemiske tilberedninger kan enkelte eller opdelte doser på fra ca. 5 til ca. 2500 mg, 15 fortrinsvis ca. 10 til 2000 mg/1-4 gange daglig, indgives i systemiske doseringsformer som beskrevet ovenfor i tilstrækkelig lang tid til at lette heling og reducere hudbeskadigelse.
Opfindelsen vil i det følgende bliver belyst i ek-20 sempler, der illustrerer foretrukne udførelsesformer for den foreliggende opfindelse.
Eksempel 1
Nedenfor beskrives en thromboxan-A2*-receptorantago-25 nist-tilberedning, der er egnet til oral indgift.
1000 tabletter, der hver indeholder 400 mg thromboxan-A2~antagonist, fremstilles ud fra følgende bestanddele: [IS-[1/3,2α(5A) ,3a,4/3] ]-7-[3-[ [ [ [ (1-Oxoheptyl) -.. amino] acetyl] amino] methyl] -7-oxabicyclo [2,2,1]-30 hept-2-yl]-5-heptensyre (SQ 30.741) 400 g
Majsstivelse 50 g
Gelatine 7/5 g
Avicel (mikrokrystallinsk cellulose) 25 g
Magnesiumstearat 2,5 g 35 Thromboxan-antagonisten og majsstivelse blandes med en vandig opløsning af gelatinen. Blandingen tørres og for-
I DK 175207 B1 I
i 6 I
I males til et fint pulver. Avicel og derpå magnesiumstearat I
I blandes med granulatet. Dette komprimeres derpå til tabletter I
I og giver 1000 tabletter, der hver indeholder 400 mg aktivt I
I stof. I
I 5 i
I Eksempel 2-3 I
I Folgende topiske aerosoltilberedninger kan anvendes I
I til behandling af hudbeskadigelser. I
I 10 Mængde Spec.mængde I
I Eksempel 2 væqt% væqt%
I SQ 30.471 0,01-1 0,05 I
I Ethanol 5-50 25 I
I Freon 11 el. 114 50:50 I
I 15 Freon' 12 blanding 50-95 74,95 I
I Eksempel 3 I
I SQ 30.741 0,01-1 I
I Overf1.akt. middel (oleinsyre, oleyl- I
I 20 alkohol, lecithin) g.s. I
I Vand g.s. I
I Freon 11 el. 114 50:50 I
I Frieon 12 blanding g. s. 100% I
I 25 Eksempel 4 I
I En injicerbar oplosning til brug ved indgift af throm- I
I boxan-A2-receptorantagonist fremstilles på folgende måde. I
I [lS-[lcr, 1/7(5Z) , 3/3,4a] ]-7-[3-[ [2-(phenylamino)carbonyl- I
I hydrazino)methyl)-7-oxabicyclo[2,2,l)hept-2-yl]- I
I
I 30 5-heptensyre (SQ 29.548) 2500 mg
I Methylparaben 5 mg I
I Propylparaben 1 mg
I Natriumchlorid 25 g I
I Vånd til injektion, op til 1 liter I
I 35 Thromboxan-A2-antagonisten, konserveringsmidlerne og I
I natriumchlorid oploses i 3 liter injektionsvand, og derpå I
DK 175207 B1 7 bringes voluminet op på 5 liter. Oplosningen filtreres gennem et sterilt filer og fyldes aseptisk i forud steriliserede hætteglas, som derpå lukkes med forud steriliserede gummiluk-ker. Hvert hætteglas indeholder en koncentration på 75 mg 5 aktivt stof pr. 150 ml opløsning.
Eksempel 5
En injektionstilberedning til brug ved behandling af hudbeskadigelse fremstilles som beskrevet i eksempel 4 med 10 undtagelse af, at den anvendte thromboxan-A2-antagonist er phenoxyalkyl-carboxylsyren 4-[2-(benzensulfamido) ethyl]phen-oxyeddikesyre, der er genstand for USA patentskrift nr.
•4.258.058.
15 Eksempel 6
En injektionstilberedning til brug ved behandling af hudbeskadigelse fremstilles som beskrevet i eksempel 4 med undtagelse af, at den anvendte thromboxan-A2-antagonist er [ IS- [ la , 20 ( Z) , 30,4a] ] -7-[ 3-[ [ [ [ (4-cyclohexyl-l-oxobutyl) -2 0 aroino]acetyl]amino]methyl]-7-oxobicylco[2,2,1]hept-2-yl] -5-heptensyre.
Eksempel 7
En oral, injicerbar eller topisk opløsning til brug 25 ved behandling af hudbeskadigelse fremstilles på følgende måde.
Der fremstilles en SQ 30.741-opløsning ved en koncentration på 50 mg/ml ved at suspendere en passende mængde SQ ^ 30.741 i destilleret vand og justere pH til 12,0 med IN
30 NaOH, hvorved der fås en klar opløsning. Derpå returtitreres opløsningen til pH 8,0 med fortyndet phosphorsyre, voluminet . justeres med destilleret vand, og opløsningen filtreres gennem et 0,45 μτα filter. Opløsninger i koncentrationsinter- / vallet 0,1-10,0 mg/ml fremstilles ved seriefortynding af 35 den filtrerede 50 mg/ml opløsning.
I DK 175207 B1 I
i 8 I
I Eksempel 8 I
I På følgende måde fremstilles en oral, injicerbar I
I eller topisk suspension til brug ved behandling af hudbe- I
I skadigelse. I
I 5 Der fremstilles SQ 30.741-suspensioner i 1% carboxy- I
I methylcellulose-(CMC)-oplosning. 1% CMC-opløsning fremstil- I
I les i destilleret vand og titreres til pH 8,2 med natrium- I
I bicarbonat. 1%'s CMC-opløsningen sættes langsomt til en I
I passende mængde SQ 30.741-pulver i volumetrisk kolbe, så at I
I 10 der fås en homogen dispersion. Voluminet fyldes efter med I
I 1% CMC. I
I Følgende yderligere topiske tilberedninger fremstilles I
I som beskrevet nedenfor. I
I 15 Eksempel 9 I
I Cream indeholdende 0,5% SQ 30.741.
I SQ 30.741, mikroniseret 0,5 g I
I Dibutylsebacat 5 g I
I Glycerylstearat 4 g I
I 20 Hvid voks 4 g I
I Promulgen, type D (PEG fedtsyrealkoholether)- I
I Cetearyl-alkohol & Ceteareth-20 (Robinson- I
I Wagner) 7 g I
I Propylenglycol 15 g I
I 25 Diroethicon 350 1 g I
I Renset vand indtil 100,0 g I
I SQ 30.741 blandes med dibutylsebacat under mild varme I
I på ikke over 50°C. Glycerylstearatet, den hvide voks, Dime-
I I
I 30 thicon 350 og Promulgen smeltes sammen og opvarmes til 75- I
I 80°C, afkøles til stuetemperatur og blandes derpå med oven- I
I nævnte opløsning af propylenglycolen. Den opnåede blanding I
I sættes til renset vand under kraftig omrøring, så at der I
I emulgeres og omrøres. Derpå tilsættes tilstrækkeligt renset I
I 35 vand, så at der fås 100 g. Blandingen fortsættes derpå med I
I lav hastighed under størkningstrinnet, indtil creamen har I
DK 175207 B1 9 nået stuetemperatur.
Eksempel 10
Lotion 0,7%.
5 SQ 30.741 0,7 g
Dibutylsebacat 7 g
Polysorbat 60 5 g
Natriumcarboxymethylcellulose 5 g 10 Cetylalkohol 2 g
Methylparaben 0,3 g
Propylparaben 0,03 g
Renset vand indtil 100 g 15 SQ 30.741 og parabener blandes med dibutylsebacat under mild varme, ikke over 50°C, og smeltes sammen, og der tilsættes Polysorbat 60 og cetylalkohol. Vand opvarmes til 80°C for at opløse natriumcarboxymethylcellulosen, der danner en vandig fase, som under kraftig omrøring sættes til olien 20 for at emulgere. Omrøring fortsættes, indtil temperaturen falder til 48°C. Der tilsættes tilstrækkeligt vand ved 50°C til, at der fås 100 g. Blandingen fortsættes ved lav ha- i stighed, så at blandingen størkner, indtil lotionen har nået stuetemperatur.
25
Eksempel 11
Salve, 0,5%.
SQ 30.741 0,5 g 30 (a) Dibutylsebacat 50 g (b) Mineralolie 44 g (a) og (b) geleres med polyethylen 5 g
Titandioxid 0,5 g 35 SQ 30.741 blandes med dibutylsebacat og sættes til en geleret blanding af mineralolie og polyethylen indehol-
I DK 175207 B1 I
I 10 I
I dende titandioxid. I
I Eksempel 12 I
I Lotion, 0,5%. I
I 5 I
I SQ 29.548 0,5 g I
I Dimethylisosorbid U.S.P. 45g I
I Vaseline, U.S.P. 3 g I
I Promulgen, type D (PEG fedtsyrealkoholether)- I
I 10 Cetearylalkohol & Ceteareth-20 (Robinson- I
I Wagner) 1,5 g I
I Methylparaben, U.S.P. 0,15 g I
I Propylparaben 0,02 g I
I Renset vand indtil 100 g I
I 15 I
I SQ 29.548 og parabenerne blandes med dimethylisosorbid I
I ved mild varme ikke over 50°C. Vaseline og Promulgen smel- I
I tes sammen og opvarmes til 75-80°C, afkøles til stuetempe- I
I ratur og blandes derpå med ovennævnte opløsning, ben opnåede I
I 20 blanding sættes til renset vand under kraftig omrøring for I
I at emulgere. Omrøringen fortsættes, indtil temperaturen er I
I faldet til 48°C. Derpå tilsættes tilstrækkeligt varmt (48- I
I 50°C) renset vand, til at der fås 100 g. Blandingen fortsæt- I
I tes derpå ved lav hastighed under størkningstrinnet, indtil I
I 25 lotionens temperatur når 42°C. I
I Eksempel 13 I
I Topisk cream, 0,1%. I
I SQ 30.741 0,1 g I
I B
30 Dimethylisoforbid 55 g
I Vaseline, U.S.P. 16 g I
I Promulgen, type D (PEG fedtalkoholether) 8 g I
I Methylparaben 0,15 g I
I Propylparaben 0,02 g I
I 35 Renset vand indtil 100 g I
I SQ 30.741 og parabenerne blandes med dimethylisosorbid I
11 DK 175207 B1 ved svag varme, ikke over 50°C. Vaseline og Promulgen D smeltes sammen. Efter sammenblanding sættes blandingen til dimethylisosorbidopløsningen under grundig sammenblanding, idet temperaturen holdes under 50°C. Under kraftig omrøring 5 sættes vand til oliefasen, så at den emulgeres. Omrøringen fortsættes, indtil temperatur falder til 48°C. Der tilsættes tilstrækkeligt vand ved 50®C til, at der fås 100 g.
Omrøringen forsættes ved lav hastighed, så at blandingen størkner, indtil temperaturen falder til 42°C.
10
Eksempel 14
Salve, 0,25%.
SQ 29.548 0,25 g 15 Dimethylisosorbid « 1 g
Titandioxid 0,5 g
Plastibase 50W (mineralolie) (95%) geleret med polyethylen (5%) indtil 100 g 20 SQ 29.548 blandes med dimethylisosorbid ved svag varme, ikke over 50°C. Opløsningen afkøles til stuetemperatur, og titandioxid dispergeres homogent i olien. Suspensionen inkorporeres i Plastibase ved lay blandingshastighed, indtil den er homogen og danner en salve.
25
Eksempel 15
Lipofil klar gel, 0,5%.
SQ 30.741 0,5 g 30 Dimethylisosorbid 1 g
Mineralolie, U.S.P. 80,375 g
Paraflint RG (højtsmeltende paraffinvoks),
Moor and Munger 6 g
Span 65 (Sorbitan-tristearat, ICI) 3,6 g
Paraflint RG og Span 65 smeltes og opvarmes til 100°C.
35
I DK 175207 B1 I
I 12 I
I Den smeltede blanding inkorporeres i varm (100°C) mineralolie I
I og blandes godt. Oliens temperatur bringes hurtigt på 50°C I
I til dannelse af en gel. I
I SQ 30.741 blandes med dimethylisosorbid ved svag I
I 5 varme, olien afkøles til stuetemperatur og inkorporeres I
I derpå homogent i gelen. I
I I
I Eksempel 16 I
I Lipofil stift. I
I 10 I
I SQ 30.741 0,1 g I
I Dimethylisosorbid 2,5 g I
I Carnaubavoks 8 g I
I Bi voks 16 g I
I 15 Vaseline 3,4 g I
I Ceraphyl 365, Van Dyk (isostearyl I
I neo pentanoat) 10 g I
I SQ 30.741 blandes med dimethylisosorbid ved svag I
I 20 varme, ikke over 50°C. En smeltet blanding af de øvrige I
I ingredienser sættes til ovennævnte opløsning ved 50°C. Bian- I
I dingen hældes i en form og afkøles, så at blandingen størkner I
I til en stift. I
I 25 Eksempel 17-21 I
I Topiske creamer tilberedes ud fra følgende ingredi- I
I enser. I
I A. SQ 30741 I
I B. Glycerylmonostearat I
I 30 C. Cetylalkohol *' I
I D. Myristylstearat I
I E. Isopropylpalmitat I
I F. Tween 60 I
I G. Propylenglycol I
I 35 H. Vand U.S.P I
I Eks. 17 Eks. 18 Eks. 19 Eks. 20 Eks. 21 I
DK 175207 B1 13
Ingr. Vægtdele Vægtdele Vægtdele Vægtdele Vægtdele A. 0,05 0,1 112 B. 120 94 94 70 94 . 5 C. 29 22 , 22 18 22 D. 65 56 56 44 56 E. 27 22 22 18 22 F. 33 33 33 33 . 33 G. 300 400 600 700 700 10 H- 438 373 171 116 70 I* 35 59 39 71 58 * = vægt% SQ 30.741 i opløsning 15 t
Procedure 1) Myristylstearatet, ætylalkohol, glycerylmonostea-rat, isopropylpalmitat og ca. 1/3 af Tween 60 opvarmes til ca. 90°C og smeltes. 2) SQ 30741 blandes med ca. 90% af 20 propylenglycolen under svag opvarmning. 3) Resten af Tween 60 blandes med vandet, blandingen opvarmes til ca. 50°C og sættes til SQ 3 0.741/propylenglycol-blandingen, som ligeledes er ved en temperatur på ca. 90°C. 4) Oliefasen fra trin 1) i sættes til den vandige glycolfase og blandes hurtigt ved 25 ca. 90°C. Sammenblandingen fortsættes, indtil emulgeringen er fuldstændig. 5) Det øvrige SQ 30.741 opslæmmes i den resterende propylenglycol og blandes i creamen ved stuetemperatur, til denne er blevet ensartet.
I DK 175207 B1 I
I 14 I
I Eksempel 22 I
I Salve I
I Ingredienser Vaegtdele I
I Polyethylenglycol* 1500 10,0 I
I 5 Polyethylenglycol 400 10,0 I
I Polyethylenglycol 6000 distearat 2,0 I
I SQ 30.741 0,1 I
I Hvid vaseline, U.S.P. 77.9 I
I Ialt 100,0 I
I 10 * en 1:1 blanding af polyethylenglycol 300 og 1540 I
I Procedure I
I Polyethylenglycolerne og polyethylenglycol 6000 di- I
I stearat kombineres og opvarmes under omrøring til 65°C i en I
I passende kedel af rustfrit stål eller foret med glas og I
I 15 udstyret til opvarmning og afkøling. SQ 30.741 sættes derpå I
I til den smeltede blanding, og opvarmningen og omrøringen I
I fortsættes i ca. 20 min. Derpå tilsættes vaselinen, der er I
I blevet smeltet separat. Når tilsætningen er tilendebragt, I
I genoptages omrøringen. Derpå afbrydes opvarmningen, og sam- I
I 20 mensætningen får lov at køle af under omrøring, indtil størk- I
ningert begynder (ved ca. 46°C). Den opnåede salve har vase- I
I " line som kontinuerlig fase, og polyethylenglycolen med SQ I
I 30.741 opløst deri som den diskontinuerlige fase. I
I Der kan også fremstilles tilfredstillende tilbered- I
I 25 ninger ved den omvendte procedure, dvs. at glycolfasen sættes I
I til den smeltede vaselinefase. I
I I
Claims (8)
1. Anvendelse af thromboxan-A2-antagonister til fremstilling af et farmaceutisk middel til forebyggelse eller behandling af hudbeskadigelse, kendetegnet ved, * I 5 at thromboxan-A2-antagonisten er en 7-oxabicycloheptan-sub-, stitueret amino-prostaglandinanalog.
2. Anvendelse ifølge krav 1, kendetegnet ved, at thromboxan-A2-antagonisten er en 7-oxabicyclo-heptan-substitueret diamid-prostaglandinanalog, en phenoxyalkylcar- 10 boxylsyre, en sulfonamidophenylcarboxylsyre eller en aryl- · thioalkylphenylcarboxylsyre.
3. Anvendelse ifølge krav 1,kendetegnet ved, at thromboxan-A2-antagonisten er [ IS-[Ια, 2β (5Z) , 3/3 (1E,-3R,4S),4a]]-7-[3-(3-hydroxy-4~phenyl-l-pentenyl)-7-oxabicy- 15 clo(2,2,l)hept-2-yl]-5-heptensyre.
4. Anvendelse ifølge krav 1, kendetegnet ved, at thromboxan-A2-antagonisten er [lS-[l/9,2a(5Z),3a,4/?]]- 7-[3-[[[[(1-oxoheptyl)amino]acetyl]amino]methyl]-7-oxabicy-clo [2,2,l]hept-2-yl]-5-heptensyre eller den tilsvarende 20 tetrazol.
5. Anvendelse ifølge krav 1, kendetegnet ved, at thromboxan-A2-antagonisten er [lS-[la,20(Z),30,4a] ]- 7—[3— [ [ [ [ (4-cy.clohexyl-l-oxobutyl)amino]acetyl]amino]methyl]- 7-oxabicyclo[2,2,l]hept-2-yl]-5-heptensyre.
6. Anvendelse ifølge krav 1, kendetegnet ved, at thromboxan-A2-antagonisten er [lS-[la,20(5Z), 3/9,4a] ]- 7-[3-[ [2- (phenylamino] -carbonyl]hydrazino]methyl]-7-oxabicy- v : clo[2,2,l]hept-2-yl]-5-heptensyre.
, 7. Anvendelse ifølge krav l,kendetegnet 30 ved, at thromboxan-A2-antagonisten er 4-(3-((4-chlorphenyl)-sulfonyl)propyl)benzen-eddikesyre.
8. Anvendelse ifølge krav 1, kendetegnet ved, at thromboxan-A2-antagonisten er 4-[2-(benzensulfamido)- j ethyl]phenoxyeddikesyre eller 4-[2-[4-chlorbenzensulfonami- 35 do)ethyl]-phenyleddikesyre.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/239,376 US4925873A (en) | 1988-09-01 | 1988-09-01 | Method of treating skin injuries using thromboxane A2 receptor antagonists |
US23937688 | 1988-09-01 |
Publications (3)
Publication Number | Publication Date |
---|---|
DK431589D0 DK431589D0 (da) | 1989-08-31 |
DK431589A DK431589A (da) | 1990-03-02 |
DK175207B1 true DK175207B1 (da) | 2004-07-12 |
Family
ID=22901897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK198904315A DK175207B1 (da) | 1988-09-01 | 1989-08-31 | Sårbehandlingsmidler indeholdende thromboxan A2-receptor-antagonister |
Country Status (13)
Country | Link |
---|---|
US (1) | US4925873A (da) |
EP (1) | EP0357030B1 (da) |
JP (1) | JPH02108635A (da) |
AT (1) | ATE100320T1 (da) |
AU (1) | AU632503B2 (da) |
CA (1) | CA1337930C (da) |
DE (1) | DE68912459T2 (da) |
DK (1) | DK175207B1 (da) |
HU (1) | HUT51137A (da) |
IE (1) | IE63799B1 (da) |
NZ (1) | NZ230505A (da) |
PT (1) | PT91597B (da) |
ZA (1) | ZA896558B (da) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5858684A (en) * | 1991-08-23 | 1999-01-12 | The Brigham And Women's Hospital, Inc. | Method of screening calcium receptor-active molecules |
US6001884A (en) * | 1991-08-23 | 1999-12-14 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5763569A (en) * | 1991-08-23 | 1998-06-09 | The Brigham And Women's Hospital, Inc | Calcium receptor-active molecules |
US6011068A (en) * | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5688938A (en) * | 1991-08-23 | 1997-11-18 | The Brigham & Women's Hospital, Inc. | Calcium receptor-active molecules |
US6031003A (en) * | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US5324746A (en) * | 1993-02-12 | 1994-06-28 | Mckee Rex N | Method of treating damaged mucosal and epithelial tissues with misoprostol |
US5962314A (en) * | 1993-02-23 | 1999-10-05 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
US7910624B1 (en) | 1995-03-03 | 2011-03-22 | The Trustees Of Boston University | Compositions for the treatment of blood disorders |
AU696167B2 (en) * | 1993-10-29 | 1998-09-03 | Trustees Of Boston University | Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
CA2202879C (en) | 1994-10-21 | 2005-08-30 | Bradford C. Van Wagenen | Calcium receptor-active compounds |
GB9424708D0 (en) * | 1994-12-07 | 1995-02-01 | Bristol Myers Squibb Co | Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage |
US6011000A (en) * | 1995-03-03 | 2000-01-04 | Perrine; Susan P. | Compositions for the treatment of blood disorders |
ES2201300T3 (es) * | 1996-05-01 | 2004-03-16 | Nps Pharmaceuticals, Inc. | Compuestos activos frente a receptores de iones inorganicos. |
US5994399A (en) * | 1997-03-27 | 1999-11-30 | Mckee; Rex N. | Method of regenerating collagen-containing tissues with misoprostol |
WO1999040883A2 (en) * | 1998-02-11 | 1999-08-19 | Faller Douglas V | Compositions and methods for the treatment of cystic fibrosis |
US7241746B2 (en) * | 2003-08-06 | 2007-07-10 | Regena Therapeutics, Lc | Method and composition for treating periodontal disease |
WO2010105112A1 (en) * | 2009-03-11 | 2010-09-16 | Hemaquest Pharmaceuticals, Inc. | Detection of short-chain fatty acids in biological samples |
US20110086869A1 (en) | 2009-09-24 | 2011-04-14 | The Trustees Of Boston University | Methods for treating viral disorders |
WO2011072086A1 (en) | 2009-12-08 | 2011-06-16 | Hemaquest Pharmaceuticals, Inc. | Methods and low dose regimens for treating red blood cell disorders |
WO2011113013A2 (en) | 2010-03-11 | 2011-09-15 | Hemaquest Pharmaceuticals, Inc. | Methods and compositions for treating viral or virally-induced conditions |
WO2012105823A1 (en) | 2011-02-02 | 2012-08-09 | Biotropics Malaysia Berhad | Cosmetic non therapeutic use of extracts from ficus deltoidea |
JP2022536256A (ja) | 2019-05-31 | 2022-08-15 | ヴィラクタ サブシディアリー,インク. | ヒストンデアセチラーゼ阻害剤を用いてウイルス関連癌を治療する方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2809377A1 (de) * | 1978-03-04 | 1979-09-13 | Boehringer Mannheim Gmbh | Phenoxyalkylcarbonsaeure-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
US4311707A (en) * | 1979-02-12 | 1982-01-19 | American Cyanamid Company | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions |
DE3000377A1 (de) * | 1980-01-07 | 1981-07-09 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
US4537981A (en) * | 1981-11-09 | 1985-08-27 | E. R. Squibb & Sons, Inc. | 7-Oxabicycloheptane and 7-oxabicycloheptene compounds |
US4416896A (en) * | 1982-05-17 | 1983-11-22 | E. R. Squibb & Sons, Inc. | 7-Oxabicyclopheptane substituted amino prostaglandin analogs useful in the treatment of thrombolytic disease |
US4663336A (en) * | 1985-07-01 | 1987-05-05 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptane substituted diamide and its congener prostaglandin analogs useful in the treatment of thrombotic disease |
US4673685A (en) * | 1986-07-23 | 1987-06-16 | E. R. Squibb & Sons, Inc. | Hydroximic acids of 7-oxabicycloheptane substituted ethers and thioethers useful in the treatment of thrombotic disease |
US4752616A (en) * | 1987-06-29 | 1988-06-21 | E. R. Squibb & Sons, Inc. | Arylthioalkylphenyl carboxylic acids, compositions containing same and method of use |
-
1988
- 1988-09-01 US US07/239,376 patent/US4925873A/en not_active Expired - Fee Related
-
1989
- 1989-08-22 CA CA000609039A patent/CA1337930C/en not_active Expired - Fee Related
- 1989-08-28 ZA ZA896558A patent/ZA896558B/xx unknown
- 1989-08-28 IE IE275589A patent/IE63799B1/en not_active IP Right Cessation
- 1989-08-30 AT AT89116002T patent/ATE100320T1/de not_active IP Right Cessation
- 1989-08-30 DE DE68912459T patent/DE68912459T2/de not_active Expired - Fee Related
- 1989-08-30 EP EP89116002A patent/EP0357030B1/en not_active Expired - Lifetime
- 1989-08-30 AU AU40898/89A patent/AU632503B2/en not_active Ceased
- 1989-08-31 NZ NZ230505A patent/NZ230505A/en unknown
- 1989-08-31 JP JP1228178A patent/JPH02108635A/ja active Pending
- 1989-08-31 HU HU894522A patent/HUT51137A/hu unknown
- 1989-08-31 PT PT91597A patent/PT91597B/pt not_active IP Right Cessation
- 1989-08-31 DK DK198904315A patent/DK175207B1/da not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0357030A2 (en) | 1990-03-07 |
DE68912459D1 (de) | 1994-03-03 |
ATE100320T1 (de) | 1994-02-15 |
AU632503B2 (en) | 1993-01-07 |
ZA896558B (en) | 1990-05-30 |
EP0357030B1 (en) | 1994-01-19 |
JPH02108635A (ja) | 1990-04-20 |
DK431589D0 (da) | 1989-08-31 |
CA1337930C (en) | 1996-01-16 |
US4925873A (en) | 1990-05-15 |
DE68912459T2 (de) | 1994-08-04 |
PT91597B (pt) | 1995-05-04 |
AU4089889A (en) | 1990-03-08 |
DK431589A (da) | 1990-03-02 |
EP0357030A3 (en) | 1990-08-16 |
PT91597A (pt) | 1990-03-30 |
NZ230505A (en) | 1997-03-24 |
IE63799B1 (en) | 1995-06-14 |
IE892755L (en) | 1990-03-01 |
HUT51137A (en) | 1990-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK175207B1 (da) | Sårbehandlingsmidler indeholdende thromboxan A2-receptor-antagonister | |
KR100402563B1 (ko) | 에스트로겐에 민감한 질병을 치료하기 위한 조성물 및 방법 | |
US5312818A (en) | Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromboxane A2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation | |
US6017909A (en) | Salts of azelastine having improved solubility effective at treating psoriasis and providing a cytoprotective effect | |
EP0231621B1 (en) | Topical pharmaceutical composition comprising pseudomonic acid or a salt or ester thereof and a corticosteroid | |
US5686450A (en) | Use of N,N'-bis(mercaptoacetyl) hydrazine derivatives as anticataract agents | |
EP0784975B1 (en) | Use of acetylsalicylic acid in the manufacture of a drug for the treatment of skin injuries | |
US4916132A (en) | Use of dihydroergotamine and its salts for the local treatment of trophic disturbances | |
JP2004532230A (ja) | Ppar−ガンマアクチベーターを使用する瘢痕化および関連状態の処置 | |
CA2135179C (en) | Pharmaceutical compositions of alkylsulphonamides 5ht1 agonists for rectal administration | |
CA2156497A1 (en) | Agent for prophylaxis or treatment of cataract | |
KR20000070823A (ko) | 이부프로펜 및 돔페리돈을 함유하는 편두통 치료용 약제학적조성물 | |
US6063792A (en) | Methods and compositions for treating urinary incontinence using enantiomerically enriched (S)-trihexyphenidyl | |
HRP20020717A2 (en) | Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders | |
CA1336168C (en) | Method of preventing or treating toxemia in pregnancy using a thromboxane a_ receptor antagonist | |
US6110972A (en) | Methods and compositions for treating urinary incontinence using enantiomerically enriched (S)-tridihexethyl | |
JPS6026770B2 (ja) | 消化管潰瘍治療剤 | |
US5093354A (en) | Topical use of 2',4',6'-trimethoxy-4-(1-pyrrolidinyl) butyrophenone | |
GB2203041A (en) | Antiinflammatory and analgesic agents for external application | |
US5489615A (en) | Pharmaceutical ointment being free from skin irritative action and a process for the preparation thereof | |
JPH08119865A (ja) | 神経線維腫症治療剤 | |
JPS6317825A (ja) | 創傷治癒促進剤 | |
DK175785B1 (da) | Topicale formuleringer omfattende benzimidazoler og benzotriazoler | |
JPH0368009B2 (da) | ||
WO1998000139A1 (en) | Methods and compositions for treating urinary incontinence using enantiomerically enriched (s)-clidinium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PBP | Patent lapsed |
Country of ref document: DK |